Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Company through its representatives shall be participating in the 'JM Financial India Conference 2024' and shall be meeting various investors on February 28, 2024 at Singapore. Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is further to our earlier letter dated February 09, 2024, regarding Video/Audio recordings of Earnings call of the Company for the quarter ended December 31, 2023, held on February 09, 2024, please find enclosed herewith the transcript of the said Earnings call. Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Company through its representatives shall be participating in the 'Chasing Growth 2024 Kotak Conference' and shall be meeting various investors on February 20, 2024 at Mumbai.
Aster DM surges 8% to new 52-week high; stock up 119% in a year
Aster DM Healthcare on February 9 reported its first increase in quarterly profit since the first quarter of FY23 on the back of strong performance in the company's domestic hospitals segment. Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, please find enclosed presentation to be made to investors in the following meetings: 1. Axis Capital Conference 2. IIFL Conference Aster DM Healthcare Results Earnings Call for Q3FY24
Conference Call with Aster DM Healthcare Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Ms. Alisha Moopen Aster DM Healthcare Ltd - 540975 - Video/Audio Recording Of Earnings Call For The Quarter Ended December 31, 2023
With reference to the captioned subject, please be informed that the Earnings call of the Company for the quarter ended December 31, 2023, was held today i.e, February 09, 2024, and the Video/Audio Recording with respect to Earnings Call is available on the website of the Company.
Aster DM Healthcare Q3 Net Profit Rises 29% At Rs 179 Crore
The healthcare provider had reported a net profit of Rs 139 crore in the year-ago period. Q3FY24 & 9MFY24 Quarterly Result Announced for Aster DM Healthcare Ltd.
Healthcare facilities company Aster DM Healthcare announced Q3FY24 & 9MFY24 results: Financial Highlights for Q3FY24: Operational revenue grew 16% YoY to Rs 3,711 crore Vs. Rs 3,192 crore in Q3FY23. Operating EBITDA grew 28% YoY to Rs 583 crore Vs. Rs. 456 crore in Q3FY23. PAT (excluding losses from new hospital and non-recurring costs) grew 53% YoY to Rs 213 crore Vs. 139 crore in Q3FY23. Financial Highlights for 9MFY23: Operational revenue grew 18% YoY to Rs 10,243 crore Vs. Rs 8,671 crore in 9MFY23. Operating EBITDA grew 28% YoY to Rs 1,375 crore Vs. Rs 1,076 crore in 9MFY23. PAT (excluding losses from new hospitals and non-recurring costs) grew 45% YoY to Rs 335 crore Vs. Rs 231 crore in 9MFY23. Commenting on the results, Dr. Azad Moopen, Founder, Chairman and Managing Director, Aster DM Healthcare, said, “We extend our heartfelt gratitude to our shareholders for their resounding endorsement of our decision to segregate our GCC operations. This overwhelming support fuels our drive to enhance and expand our operations in India, reaffirming our commitment to the trust they have placed in our strategic vision. In Q3FY24, our India business showcased 23% YoY revenue growth, surging to Rs 949 crore This growth was catalyzed by the expansion of over 750 beds within the past year. Through diligent cost optimization initiatives and leveraging operational efficiencies, we achieved 37% YoY increase in Operating EBITDA in Q3FY24, elevating our hospitals' Operating EBITDA margins to 19.8% and contributing to more than doubling the Net Profit after taxes for the quarter. I am also glad to mention that our flagship Aster Medcity hospital has been recognized as the No.1 'Best Multi-specialty Hospital Emerging' by The Week-Hansa Research 2023, a testament to our unwavering commitment towards excellence. As we continue our journey, we remain steadfast in our pursuit of growth, with plans to increase our capacity beds to 6,600, showcasing our dedication towards further strengthening our strong position among India's leading healthcare providers." Result PDF Aster DM Healthcare Ltd - 540975 - Disclosure Under Regulation 30 Read With Schedule III Part A Clause A Of Sub-Clause 17 (B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 ('LODR Regulations')
This is in relation to the forensic investigation initiated by the Company in furtherance to the anonymous whistle blower complaint received by the Company relating to Wahat Al Aman Home Healthcare LLC ("Wahat"), an overseas subsidiary of the Company, which was intimated to Stock Exchanges on November 14, 2023, under Sub-clause 17(a) of the subject mentioned regulation. The Company, on the instance of the Audit Committee, had engaged M/s. BDO UAE ("BDO") for undertaking the investigation in this regard. The Investigation Report by BDO along with company''s management comments were placed at the Board Meeting held on February 08, 2024. The same is attached herewith. Kindly take the above said information on record.